![Chynops Pharma Pregabalin](https://www.pharmacompass.com/image/flap/chynops-pregabalin-desktop-headergif-5652.gif)
![Chynops Pharma Pregabalin](https://www.pharmacompass.com/image/flap/chynops-pregabalin-mobgif-72103.gif)
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
EU WC
Listed Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
USFDA approved generic version of Pregabalin treatment of fibromyalgia. It binds to the alpha2-delta subunit which is involved in anti-nociceptive and antiseizure effects.
Lead Product(s): Pregabalin
Therapeutic Area: Musculoskeletal Product Name: Lyrica-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 25, 2024
Details:
Lyrica-Generic (pregabalin) is a calcium channel alpha-2/delta-1 subunit binder, indicated for Neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia & fibromyalgia.
Lead Product(s): Pregabalin
Therapeutic Area: Neurology Product Name: Lyrica-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 21, 2024
Details:
USFDA approved generic version of Pregabalin treatment of fibromyalgia. It binds to the alpha2-delta subunit which is involved in anti-nociceptive and antiseizure effects.
Lead Product(s): Pregabalin
Therapeutic Area: Musculoskeletal Product Name: Lyrica-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 21, 2024
Details:
Pregabalin Prolonged Release Tablets is a unique formulation helps in increasing patient's adherence, it is the backbone medication indicated in the treatment of Neuropathic pain.
Lead Product(s): Pregabalin
Therapeutic Area: Neurology Product Name: Lyrica CR-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 22, 2023
Details:
Lyrica-Generic (pregabalin) is a calcium channel alpha-2/delta-1 subunit binder, indicated for Neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia & fibromyalgia.
Lead Product(s): Pregabalin
Therapeutic Area: Neurology Product Name: Lyrica-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 30, 2023
Details:
AFD-NP is a combination of Nortriptyline and Pregabalin which has approved for the treatment of moderate to severe neuropathic pain.
Lead Product(s): Pregabalin,Nortriptyline
Therapeutic Area: Neurology Product Name: AFD-NP
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2023
Details:
Lyrica-Generic (pregabalin) is a calcium channel alpha-2/delta-1 subunit binder, indicated for Neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia & fibromyalgia.
Lead Product(s): Pregabalin
Therapeutic Area: Neurology Product Name: Lyrica-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 22, 2022
Details:
Lyrica-Generic (pregabalin) is a calcium channel alpha-2/delta-1 subunit binder, indicated for Neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia & fibromyalgia.
Lead Product(s): Pregabalin
Therapeutic Area: Neurology Product Name: Lyrica-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 10, 2022
Details:
Pregabalin, to market a generic equivalent of Lyrica® Capsules, is used to treat pain caused by nerve damage due to diabetes or to shingles (herpes zoster) infection.
Lead Product(s): Pregabalin
Therapeutic Area: Neurology Product Name: Pregabalin-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 06, 2022
Details:
With the acquisition, Endo controls all remaining development, approval, launch and commercialization activities for the product candidates, NVK009 (Gabapentin). Endo's Par Sterile Products business will commercialize the products in the United States.
Lead Product(s): Gabapentin,Pregabalin,Paracetamol
Therapeutic Area: Neurology Product Name: NVK009
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Endo International
Deal Size: $35.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition May 02, 2022
Details:
XG005 is a drug conjugate of naproxen and pregabalin which is being investigated for the management of acute pain.
Lead Product(s): Pregabalin,Naproxen
Therapeutic Area: Neurology Product Name: XG005
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 22, 2020
Details:
Lyrica-Generic (pregabalin) is a calcium channel alpha-2/delta-1 subunit binder, indicated for Neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia & fibromyalgia.
Lead Product(s): Pregabalin
Therapeutic Area: Neurology Product Name: Lyrica-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 24, 2020